Compass (COMP) stock fell 2.4% in Friday midday trading following a report that Senator Elizabeth Warren (D-MA) questioned ...
Compass Pathways announced that its investigational psilocybin treatment has successfully met its primary endpoint in a Phase ...
Lawmakers urge DOJ to detail its review of the $1.6B Compass-Anywhere merger, citing risks to competition and housing costs.
Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical ...
Compass Point is pleased to announce the expansion of its Real Estate Research Team with the addition of Mr. Robert ...
Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the ...
Compass Pathways shares surged Tuesday after the company said its psilocybin therapy for depression met its primarily goals in recent trials. Shares traded 34% higher ahead of the morning bell at ...
The multinational coffee company will continue to operate 17 D.C.-area cafes under the Compass brand.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results